Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 23;71(7):e200-e201.
doi: 10.1093/cid/ciaa313.

Shall We Dance? Extending TANGO's Results to Clinical Practice

Alberto Borghetti  1 , Arturo Ciccullo  2 , Gianmaria Baldin  3 , Stefano Rusconi  4 , Amedeo Capetti  5 , Gaetana Sterrantino  6 , William Gennari  7 , Cristina Mussini  8 , Vanni Borghi  8 , Simona Di Giambenedetto  1   2
Affiliations

Shall We Dance? Extending TANGO's Results to Clinical Practice

Alberto Borghetti et al. Clin Infect Dis. .
No abstract available

PubMed Disclaimer

References

    1. Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis 2018; 66:1794–7. - PMC - PubMed
    1. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: Phase 3, randomized, non-inferiority TANGO study. Clin Infect Dis 2020. doi:10.1093/cid/ciz1243 - DOI - PMC - PubMed
    1. Maggiolo F, Gulminetti R, Pagnucco L, et al. Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis 2017; 17:215. - PMC - PubMed
    1. Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine (Baltimore) 2019; 98:e16813. - PMC - PubMed
    1. Borghetti A, Moschese D, Cingolani A, et al. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure. HIV Med 2019; 20:624–7. - PubMed